Stryker (NYSE:SYK) Price Target Cut to $400.00 by Analysts at JPMorgan Chase & Co.

Stryker (NYSE:SYK) had its price objective lowered by JPMorgan Chase & Co. from $445.00 to $400.00 in a report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical technology company’s stock.

Several other equities analysts have also weighed in on SYK. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. TD Cowen lowered shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective on the stock. in a research report on Monday, January 26th. Jefferies Financial Group reaffirmed a “buy” rating and set a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, Truist Financial cut their price objective on shares of Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $401.43.

Stryker Stock Down 6.3%

SYK traded down $19.70 during midday trading on Friday, hitting $295.43. 4,518,113 shares of the company’s stock traded hands, compared to its average volume of 1,836,681. The company has a market cap of $113.15 billion, a PE ratio of 35.17, a price-to-earnings-growth ratio of 1.84 and a beta of 0.92. The stock’s fifty day simple moving average is $345.67 and its 200-day simple moving average is $356.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker has a one year low of $294.55 and a one year high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.74%. Stryker’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker will post 14.91 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were given a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 41.90%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Institutional investors have recently modified their holdings of the company. Brighton Jones LLC increased its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new position in Stryker during the second quarter worth $205,000. Marshall Wace LLP increased its position in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares during the period. Nebula Research & Development LLC bought a new position in Stryker during the second quarter worth $219,000. Finally, HUB Investment Partners LLC bought a new position in Stryker during the second quarter worth $253,000. Institutional investors own 77.09% of the company’s stock.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY?2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer?term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near?term upside expectations and add selling pressure. Article Title

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.